SecBot SecBot
6-K ·Filed Aug 20, 2026

EVAX

Evaxion A/S
NEUTRAL
Impact 4/10
Horizonweeks Processed2mo ago SEC0001171843-26-005672
Actionable Insight • Neutral

Monitor the EVX-01 three-year data presentation at ESMO in October 2026 as the next major catalyst. The current cash runway into H2 2027 provides a long enough window for data readouts but leaves no margin for delays. The ATM program remains available for up to $45.5M in additional sales, creating ongoing dilution risk. No near-term trading catalyst until ESMO.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.28
T+0 close · Aug 20, 2026 · via day close
Latest settled
−16.46%
T+60 · $2.74
Vs SPY
−15.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 20 $3.28entry
  2. T+1 · 3mo ago +0.91%α +0.51% · $3.31
  3. T+5 · 3mo ago −3.96%α −5.08% · $3.15
  4. T+20 · 2mo ago −0.30%α −0.30% · $3.27
  5. T+60 · 4d ago −16.46%α −15.38% · $2.74
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion reported Q2 2026 results in line with expectations: net loss narrowed to $3.7M (vs $4.8M YoY), cash burn continues with $14.0M cash on hand funding operations into H2 2027. Pipeline progress includes upcoming 3-year EVX-01 data at ESMO and new preclinical programs (EVX-04, EVX-05, EVX-V1), but the company remains pre-revenue with no near-term catalysts that change the fundamental cash-burn story. A post-period ATM sale of $1.5M adds modest dilution. The combination of steady cash burn, pre-revenue status, and pipeline milestones that are months away suggests limited near-term catalysts for the stock.

Key Facts

  • Net loss of $3.7M for Q2 2026, improved from $4.8M in Q2 2025
  • Cash and cash equivalents of $14.0M as of June 30, 2026, down from $18.4M at March 31, 2026
  • Cash runway unchanged: funds operations into second half of 2027
  • No revenue recorded for Q2 2026
  • Post-period: sold 505,005 ADSs at $3.1533/ADS for net proceeds of ~$1.5M via ATM
  • Upcoming catalyst: 3-year clinical data for EVX-01 at ESMO Congress 2026 in October
  • Pipeline expansion with EVX-05 (glioblastoma) and preclinical data for EVX-04 (AML) and EVX-V1 (CMV)
  • Total equity declined to $9.5M from $17.0M at Dec 31, 2025
  • R&D expenses $2.3M, G&A expenses $1.5M for Q2 2026

Financial Impact

Net loss of $3.7M in Q2 2026; cash burn of $8.7M in H1 2026; post-period ATM raised ~$1.5M

cashequitynet loss

Risk Factors

  • Cash burn continues with no revenue; additional ATM sales will dilute existing shareholders
  • Pre-revenue clinical-stage company with no guaranteed path to commercialization
  • Pipeline milestones (EVX-01 data, EVX-04 IND filing) are months away and binary in nature
  • Equity declined from $17.0M to $9.5M in six months; negative equity trajectory if losses persist

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 11 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (EVAX), Batch item 10001171843-26-005672
Document: f6k_082026.htm0001171843-26-005671
Document: 0001171843-26-005672-index-headers.html0001171843-26-005672
Document: 0001171843-26-005672-index.html0001171843-26-005672
Document: 0001171843-26-005672.txt0001171843-26-005672
6-K Filing (EVAX), Batch item 60001171843-26-005671
Exhibit: ex_1006845.htm0001171843-26-005672
Document: evax20260819_6k.htm0001171843-26-005672
Document: 0001171843-26-005671-index-headers.html0001171843-26-005672
Document: 0001171843-26-005671-index.html0001171843-26-005672
Document: 0001171843-26-005671.txt0001171843-26-005672

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 20, 2026